Pulmonary Hypertension in Bronchopulmonary Dysplasia

Overview

Journal Pediatr Res

Specialties Biology
Pediatrics

Date 2020 Jun 11

PMID 32521539

Citations 80

Authors

Georg Hansmann

Hannes Sallmon

Charles C Roehr

Stella Kourembanas

Eric D Austin

Martin Koestenberger

Affiliations

Soon will be listed here.

Abstract

Bronchopulmonary dysplasia (BPD) is a major complication in prematurely born infants. Pulmonary hypertension (PH) associated with BPD (BPD-PH) is characterized by alveolar diffusion impairment, abnormal vascular remodeling, and rarefication of pulmonary vessels (vascular growth arrest), which lead to increased pulmonary vascular resistance and right heart failure. About 25% of infants with moderate to severe BPD develop BPD-PH that is associated with high morbidity and mortality. The recent evolution of broader PH-targeted pharmacotherapy in adults has opened up new treatment options for infants with BPD-PH. Sildenafil became the mainstay of contemporary BPD-PH therapy. Additional medications, such as endothelin receptor antagonists and prostacyclin analogs/mimetics, are increasingly being investigated in infants with PH. However, pediatric data from prospective or randomized controlled trials are still sparse. We discuss comprehensive diagnostic and therapeutic strategies for BPD-PH and briefly review the relevant differential diagnoses of parenchymal and interstitial developmental lung diseases. In addition, we provide a practical framework for the management of children with BPD-PH, incorporating the modified definition and classification of pediatric PH from the 2018 World Symposium on Pulmonary Hypertension, and the 2019 EPPVDN consensus recommendations on established and newly developed therapeutic strategies. Finally, current gaps of knowledge and future research directions are discussed. IMPACT: PH in BPD substantially increases mortality. Treatment of BPD-PH should be conducted by an interdisciplinary team and follow our new treatment algorithm while still kept tailored to the individual patient. We discuss recent developments in BPD-PH, make recommendations on diagnosis, monitoring and treatment of PH in BPD, and address current gaps of knowledge and potential research directions. We provide a practical framework, including a new treatment algorithm, for the management of children with BPD-PH, incorporating the modified definition and classification of pediatric PH (2018 WSPH) and the 2019 EPPVDN consensus recommendations on established and newly developed therapeutic strategies for BPD-PH.

Citing Articles

Risk Factors Associated With the Development of Late Pulmonary Artery Hypertension in Extremely Premature Infants.

Condit P, Hokanson J, Balasubramaniam V, McCulley D, Lasarev M, Lamers L Pediatr Pulmonol. 2025; 60(2):e27501.

PMID: 39945565 PMC: 11823566. DOI: 10.1002/ppul.27501.

[Prognosis of bronchopulmonary dysplasia].

Zhou Y, Wang T, Fu X, Peng B, Fu Z Zhongguo Dang Dai Er Ke Za Zhi. 2025; 27(1):115-120.

PMID: 39825661 PMC: 11750241. DOI: 10.7499/j.issn.1008-8830.2406004.

Scoping review of initiation criteria for inhaled nitric oxide in preterm infants (born <34 weeks) after 7 days of age.

Kato S, Minamitani Y, Hosokawa M, Nakashima T, Iwatani S, Hirata K BMJ Open. 2025; 14(12):e087740.

PMID: 39806669 PMC: 11683894. DOI: 10.1136/bmjopen-2024-087740.

Pulmonary vasodilator use in very preterm infants in United States children's hospitals.

Vega T, Huber M, Jensen E, Avitabile C, Lorch S, Gibbs K Res Sq. 2024; .

PMID: 39678327 PMC: 11643327. DOI: 10.21203/rs.3.rs-5492163/v1.

Purinergic P2X7 receptor mediates hyperoxia-induced injury in pulmonary microvascular endothelial cells via NLRP3-mediated pyroptotic pathway.

Zeng W, Deng Z, Li H, Gao S, Ju R Open Med (Wars). 2024; 19(1):20241097.

PMID: 39655049 PMC: 11627065. DOI: 10.1515/med-2024-1097.

References

Stoll B, Hansen N, Bell E, Walsh M, Carlo W, Shankaran S . Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993-2012. JAMA. 2015; 314(10):1039-51. PMC: 4787615. DOI: 10.1001/jama.2015.10244. View

Lignelli E, Palumbo F, Myti D, Morty R . Recent advances in our understanding of the mechanisms of lung alveolarization and bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2019; 317(6):L832-L887. DOI: 10.1152/ajplung.00369.2019. View

Weismann C, Asnes J, Bazzy-Asaad A, Tolomeo C, Ehrenkranz R, Bizzarro M . Pulmonary hypertension in preterm infants: results of a prospective screening program. J Perinatol. 2017; 37(5):572-577. DOI: 10.1038/jp.2016.255. View

Mourani P, Sontag M, Younoszai A, Miller J, Kinsella J, Baker C . Early pulmonary vascular disease in preterm infants at risk for bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2014; 191(1):87-95. PMC: 4299632. DOI: 10.1164/rccm.201409-1594OC. View

Khemani E, McElhinney D, Rhein L, Andrade O, Lacro R, Thomas K . Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics. 2007; 120(6):1260-9. DOI: 10.1542/peds.2007-0971. View

Ong M, Abman S, Austin E, Feinstein J, Hopper R, Krishnan U . Racial and Ethnic Differences in Pediatric Pulmonary Hypertension: An Analysis of the Pediatric Pulmonary Hypertension Network Registry. J Pediatr. 2019; 211:63-71.e6. PMC: 6776463. DOI: 10.1016/j.jpeds.2019.04.046. View

Nakanishi H, Uchiyama A, Kusuda S . Impact of pulmonary hypertension on neurodevelopmental outcome in preterm infants with bronchopulmonary dysplasia: a cohort study. J Perinatol. 2016; 36(10):890-6. PMC: 5050265. DOI: 10.1038/jp.2016.108. View

Choi E, Shin S, Kim E, Kim H . Developmental outcomes of preterm infants with bronchopulmonary dysplasia-associated pulmonary hypertension at 18-24 months of corrected age. BMC Pediatr. 2019; 19(1):26. PMC: 6337852. DOI: 10.1186/s12887-019-1400-3. View

Lagatta J, Hysinger E, Zaniletti I, Wymore E, Vyas-Read S, Yallapragada S . The Impact of Pulmonary Hypertension in Preterm Infants with Severe Bronchopulmonary Dysplasia through 1 Year. J Pediatr. 2018; 203:218-224.e3. PMC: 6460906. DOI: 10.1016/j.jpeds.2018.07.035. View

10.

Goss K, Beshish A, Barton G, Haraldsdottir K, Levin T, Tetri L . Early Pulmonary Vascular Disease in Young Adults Born Preterm. Am J Respir Crit Care Med. 2018; 198(12):1549-1558. PMC: 6298636. DOI: 10.1164/rccm.201710-2016OC. View

11.

Hansmann G, Koestenberger M, Alastalo T, Apitz C, Austin E, Bonnet D . 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant. 2019; 38(9):879-901. DOI: 10.1016/j.healun.2019.06.022. View

12.

Rosenzweig E, Abman S, Adatia I, Beghetti M, Bonnet D, Haworth S . Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2018; 53(1). PMC: 6351335. DOI: 10.1183/13993003.01916-2018. View

13.

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View

14.

Simonneau G, Montani D, Celermajer D, Denton C, Gatzoulis M, Krowka M . Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2018; 53(1). PMC: 6351336. DOI: 10.1183/13993003.01913-2018. View

15.

Douschan P, Kovacs G, Avian A, Foris V, Gruber F, Olschewski A . Mild Elevation of Pulmonary Arterial Pressure as a Predictor of Mortality. Am J Respir Crit Care Med. 2017; 197(4):509-516. DOI: 10.1164/rccm.201706-1215OC. View

16.

Del Cerro M, Abman S, Diaz G, Freudenthal A, Freudenthal F, Harikrishnan S . A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ. 2011; 1(2):286-298. PMC: 3161725. DOI: 10.4103/2045-8932.83456. View

17.

Sallmon H, Moledina S, Albert D, Beghetti M, Berger R, Bonnet D . Recommendations from the Association for European Paediatric and Congenital Cardiology for training in pulmonary hypertension. Cardiol Young. 2019; 29(11):1323-1327. DOI: 10.1017/S104795111900235X. View

18.

Duijts L, van Meel E, Moschino L, Baraldi E, Barnhoorn M, Bramer W . European Respiratory Society guideline on long-term management of children with bronchopulmonary dysplasia. Eur Respir J. 2019; 55(1). DOI: 10.1183/13993003.00788-2019. View

19.

Calvier L, Chouvarine P, Legchenko E, Hoffmann N, Geldner J, Borchert P . PPARγ Links BMP2 and TGFβ1 Pathways in Vascular Smooth Muscle Cells, Regulating Cell Proliferation and Glucose Metabolism. Cell Metab. 2017; 25(5):1118-1134.e7. DOI: 10.1016/j.cmet.2017.03.011. View

20.

Thebaud B, Goss K, Laughon M, Whitsett J, Abman S, Steinhorn R . Bronchopulmonary dysplasia. Nat Rev Dis Primers. 2019; 5(1):78. PMC: 6986462. DOI: 10.1038/s41572-019-0127-7. View